Smaller Business Development Deals Are Necessary Counterpoint To Mega-Mergers
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck says licensing business will go on “as usual” in wake of Schering-Plough deal announcement.
You may also be interested in...
Merck Pumps Pipeline With $800M Cardiome Deal
FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.
Schering Helps Merck Where It’s Needed Most: The Pipeline
Bulking up the pipeline is a frequent motive for a pharmaceutical merger - but somewhat unusual for Merck, a company that has long prided itself on the strength of its R&D activity
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.